Advisory Committee on Immunization Practices (ACIP); Meeting, 71067-71068 [2021-26956]
Download as PDF
Federal Register / Vol. 86, No. 237 / Tuesday, December 14, 2021 / Notices
Complainant alleges that Respondent
violated 46 U.S.C. § 41102(c) and 46
U.S.C. 41104(a)(3) and (8) with regard to
the movement of refrigerated containers.
The full text of the complaint can be
found in the Commission’s Electronic
Reading Room at https://www2.fmc.gov/
readingroom/proceeding/21-10/.
This proceeding has been assigned to
Office of Administrative Law Judges.
The initial decision of the presiding
office in this proceeding shall be issued
by December 8, 2022, and the final
decision of the Commission shall be
issued by June 22, 2023.
2200 North Pearl Street, Dallas, Texas
75201–2272:
1. The Odom AmTex Holdings Trust,
Orange, Texas; to become a bank
holding company by acquiring Odom
AmTex, LLC, Orange, Texas, and
thereby indirectly acquiring AmTex
Bancshares, Inc., Orange, Texas; Bridge
City State Bank, Bridge City, Texas;
Peoples State Bank, Shepherd, Texas;
and Pavillion Bank, Richardson, Texas.
Board of Governors of the Federal Reserve
System, December 9, 2021.
Michele Taylor Fennell,
Deputy Associate Secretary of the Board.
[FR Doc. 2021–27044 Filed 12–13–21; 8:45 am]
JoAnne O’Bryant,
Program Analyst.
BILLING CODE 6210–01–P
[FR Doc. 2021–26992 Filed 12–13–21; 8:45 am]
BILLING CODE 6730–02–P
jspears on DSK121TN23PROD with NOTICES1
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
FEDERAL RESERVE SYSTEM
Centers for Disease Control and
Prevention
Formations of, Acquisitions by, and
Mergers of Bank Holding Companies
[Docket No. CDC–2021–0132]
The companies listed in this notice
have applied to the Board for approval,
pursuant to the Bank Holding Company
Act of 1956 (12 U.S.C. 1841 et seq.)
(BHC Act), Regulation Y (12 CFR part
225), and all other applicable statutes
and regulations to become a bank
holding company and/or to acquire the
assets or the ownership of, control of, or
the power to vote shares of a bank or
bank holding company and all of the
banks and nonbanking companies
owned by the bank holding company,
including the companies listed below.
The public portions of the
applications listed below, as well as
other related filings required by the
Board, if any, are available for
immediate inspection at the Federal
Reserve Bank(s) indicated below and at
the offices of the Board of Governors.
This information may also be obtained
on an expedited basis, upon request, by
contacting the appropriate Federal
Reserve Bank and from the Board’s
Freedom of Information Office at
https://www.federalreserve.gov/foia/
request.htm. Interested persons may
express their views in writing on the
standards enumerated in the BHC Act
(12 U.S.C. 1842(c)).
Comments regarding each of these
applications must be received at the
Reserve Bank indicated or the offices of
the Board of Governors, Ann E.
Misback, Secretary of the Board, 20th
Street and Constitution Avenue NW,
Washington DC 20551–0001, not later
than December 30, 2021.
A. Federal Reserve Bank of Dallas
(Karen Smith, Director, Applications)
VerDate Sep<11>2014
18:24 Dec 13, 2021
Jkt 256001
Advisory Committee on Immunization
Practices (ACIP); Meeting
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice of meeting and request
for comment.
AGENCY:
In accordance with the
Federal Advisory Committee Act, the
Centers for Disease Control and
Prevention (CDC) announces the
following meeting of the Advisory
Committee on Immunization Practices
(ACIP). This meeting is open to the
public. Time will be available for public
comment. The meeting will be webcast
live via the World Wide Web.
DATES: The meeting will be held on
January 12, 2022, from 10:00 a.m. to
2:30 p.m., EST (times subject to change).
The public may submit written
comments from December 14, 2021
through January 12, 2022.
ADDRESSES: You may submit comments
identified by Docket No. CDC–2021–
0132 by any of the following methods:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: Centers for Disease Control
and Prevention, 1600 Clifton Road NE,
MS H24–8, Atlanta, Georgia 30329–
4027, Attn: ACIP Meeting.
Instructions: All submissions received
must include the Agency name and
Docket Number. All relevant comments
received in conformance with the
https://www.regulations.gov suitability
policy will be posted without change to
https://www.regulations.gov, including
SUMMARY:
PO 00000
Frm 00066
Fmt 4703
Sfmt 4703
71067
any personal information provided. For
access to the docket to read background
documents or comments received, go to
https://www.regulations.gov.
Written public comments submitted
up to 72 hours prior to the ACIP
meeting will be provided to ACIP
members before the meeting.
FOR FURTHER INFORMATION CONTACT:
Stephanie Thomas, ACIP Committee
Management Specialist, National Center
for Immunization and Respiratory
Diseases, Centers for Disease Control
and Prevention, 1600 Clifton Road NE,
MS–H24–8, Atlanta, Georgia 30329–
4027; Telephone: (404) 639–8367;
Email: ACIP@cdc.gov.
SUPPLEMENTARY INFORMATION: Purpose:
The committee is charged with advising
the Director, CDC, on the use of
immunizing agents. In addition, under
42
U.S.C. 1396s, the committee is
mandated to establish and periodically
review and, as appropriate, revise the
list of vaccines for administration to
vaccine-eligible children through the
Vaccines for Children program, along
with schedules regarding dosing
interval, dosage, and contraindications
to administration of vaccines. Further,
under provisions of the Affordable Care
Act, section 2713 of the Public Health
Service Act, immunization
recommendations of the ACIP that have
been approved by the CDC Director and
appear on CDC immunization schedules
must be covered by applicable health
plans.
Matters To Be Considered: The agenda
will include discussions on cholera
vaccine, tick-borne encephalitis vaccine,
influenza vaccines, hepatitis vaccines
and respiratory syncytial virus (RSV)
vaccine. No recommendation votes are
scheduled. No Vaccines for Children
(VFC) votes are scheduled. Agenda
items are subject to change as priorities
dictate. For more information on the
meeting agenda visit https://
www.cdc.gov/vaccines/acip/meetings/
meetings-info.html.
Public Participation
Interested persons or organizations
are invited to participate by submitting
written views, recommendations, and
data. Please note that comments
received, including attachments and
other supporting materials, are part of
the public record and are subject to
public disclosure. Comments will be
posted on https://www.regulations.gov.
Therefore, do not include any
information in your comment or
supporting materials that you consider
confidential or inappropriate for public
disclosure. If you include your name,
E:\FR\FM\14DEN1.SGM
14DEN1
jspears on DSK121TN23PROD with NOTICES1
71068
Federal Register / Vol. 86, No. 237 / Tuesday, December 14, 2021 / Notices
contact information, or other
information that identifies you in the
body of your comments, that
information will be on public display.
CDC will review all submissions and
may choose to redact, or withhold,
submissions containing private or
proprietary information such as Social
Security numbers, medical information,
inappropriate language, or duplicate/
near duplicate examples of a mass-mail
campaign. CDC will carefully consider
all comments submitted into the docket.
Written Public Comment: The docket
will be opened to receive written
comments on December 14, 2021.
Written comments must be received on
or before January 12, 2022.
Oral Public Comment: This meeting
will include time for members of the
public to make an oral comment. Oral
public comment will occur before any
scheduled votes including all votes
relevant to the ACIP’s Affordable Care
Act and Vaccines for Children Program
roles. Priority will be given to
individuals who submit a request to
make an oral public comment before the
meeting according to the procedures
below.
Procedure for Oral Public Comment:
All persons interested in making an oral
public comment at the January 12, 2022
ACIP meeting must submit a request at
https://www.cdc.gov/vaccines/acip/
meetings/ no later than 11:59 p.m., EST,
January 7, 2022, according to the
instructions provided.
If the number of persons requesting to
speak is greater than can be reasonably
accommodated during the scheduled
time, CDC will conduct a lottery to
determine the speakers for the
scheduled public comment session.
CDC staff will notify individuals
regarding their request to speak by email
by January 10, 2022. To accommodate
the significant interest in participation
in the oral public comment session of
ACIP meetings, each speaker will be
limited to 3 minutes, and each speaker
may only speak once per meeting.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
VerDate Sep<11>2014
18:24 Dec 13, 2021
Jkt 256001
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2021–26956 Filed 12–13–21; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Board of Scientific Counselors, Deputy
Director for Infectious Diseases (BSC,
DDID)
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice of meeting.
AGENCY:
In accordance with the
Federal Advisory Committee Act, the
CDC announces the following meeting
for the Board of Scientific Counselors,
Deputy Director for Infectious Diseases
(BSC, DDID). This virtual meeting is
open to the public via Zoom, limited
only by the space available, which is
500 seats. Pre-registration is required by
accessing the link below in the
addresses section.
DATES: The meeting will be held on
January 19–20, 2022, from 1:00 p.m. to
5:30 p.m., EST.
ADDRESSES: Zoom virtual meeting. Preregistration is required by accessing the
link at https://cdc.zoomgov.com/
webinar/register/WN_
vXuOtDbNQIycPMScOPKvKQ.
Instructions to access the meeting will
be provided following registration.
FOR FURTHER INFORMATION CONTACT:
Hilary Eiring, MPH, Designated Federal
Officer, CDC, 1600 Clifton Road NE,
Mailstop H24–12, Atlanta, Georgia
30329–4027, Telephone: (770) 488–
3901; Email: HEiring@cdc.gov.
SUPPLEMENTARY INFORMATION:
Purpose: The Board provides advice
and guidance to the Secretary,
Department of Health and Human
Services; the Director, CDC; the Director
and the Deputy Director for Infectious
Diseases (DDID), CDC; and the Directors
of the National Center for Emerging and
Zoonotic Infectious Diseases, the
National Center for HIV, Viral Hepatitis,
STD, and TB Prevention, and the
National Center for Immunization and
Respiratory Diseases, CDC, in the
following areas: Strategies, goals, and
priorities for programs and research
within the national centers and monitor
SUMMARY:
PO 00000
Frm 00067
Fmt 4703
Sfmt 4703
the overall strategic direction and focus
of DDID and the national centers.
Matters To Be Considered: The agenda
will include updates and discussions on
recent outbreaks; updates and
discussions on CDC’s Center for
Forecasting and Outbreak Analytics,
advanced molecular detection program,
Data Modernization Initiative, and
CORE Health Equity Science and
Intervention Strategy; and other updates
and reports, including a brief report
back from the Board’s Food Safety
Modernization Act Surveillance
Working Group. Agenda items are
subject to change as priorities dictate.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2021–26954 Filed 12–13–21; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Notice of Closed Meeting
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended, and the Determination of
the Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, CDC, pursuant to
Public Law 92–463.
Name of Committee: Safety and
Occupational Health Study Section (SOHSS),
National Institute for Occupational Safety
and Health (NIOSH).
Dates: February 16–17, 2022.
Time: 11:00 a.m.—5:00 p.m., EST.
Place: Teleconference.
Agenda: The meeting will convene to
address matters related to the conduct of
Study Section business and for the study
section to consider safety and occupational
health-related grant applications.
E:\FR\FM\14DEN1.SGM
14DEN1
Agencies
[Federal Register Volume 86, Number 237 (Tuesday, December 14, 2021)]
[Notices]
[Pages 71067-71068]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-26956]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[Docket No. CDC-2021-0132]
Advisory Committee on Immunization Practices (ACIP); Meeting
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice of meeting and request for comment.
-----------------------------------------------------------------------
SUMMARY: In accordance with the Federal Advisory Committee Act, the
Centers for Disease Control and Prevention (CDC) announces the
following meeting of the Advisory Committee on Immunization Practices
(ACIP). This meeting is open to the public. Time will be available for
public comment. The meeting will be webcast live via the World Wide
Web.
DATES: The meeting will be held on January 12, 2022, from 10:00 a.m. to
2:30 p.m., EST (times subject to change). The public may submit written
comments from December 14, 2021 through January 12, 2022.
ADDRESSES: You may submit comments identified by Docket No. CDC-2021-
0132 by any of the following methods:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments.
Mail: Centers for Disease Control and Prevention, 1600
Clifton Road NE, MS H24-8, Atlanta, Georgia 30329-4027, Attn: ACIP
Meeting.
Instructions: All submissions received must include the Agency name
and Docket Number. All relevant comments received in conformance with
the https://www.regulations.gov suitability policy will be posted
without change to https://www.regulations.gov, including any personal
information provided. For access to the docket to read background
documents or comments received, go to https://www.regulations.gov.
Written public comments submitted up to 72 hours prior to the ACIP
meeting will be provided to ACIP members before the meeting.
FOR FURTHER INFORMATION CONTACT: Stephanie Thomas, ACIP Committee
Management Specialist, National Center for Immunization and Respiratory
Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road
NE, MS-H24-8, Atlanta, Georgia 30329-4027; Telephone: (404) 639-8367;
Email: [email protected].
SUPPLEMENTARY INFORMATION: Purpose: The committee is charged with
advising the Director, CDC, on the use of immunizing agents. In
addition, under 42
U.S.C. 1396s, the committee is mandated to establish and
periodically review and, as appropriate, revise the list of vaccines
for administration to vaccine-eligible children through the Vaccines
for Children program, along with schedules regarding dosing interval,
dosage, and contraindications to administration of vaccines. Further,
under provisions of the Affordable Care Act, section 2713 of the Public
Health Service Act, immunization recommendations of the ACIP that have
been approved by the CDC Director and appear on CDC immunization
schedules must be covered by applicable health plans.
Matters To Be Considered: The agenda will include discussions on
cholera vaccine, tick-borne encephalitis vaccine, influenza vaccines,
hepatitis vaccines and respiratory syncytial virus (RSV) vaccine. No
recommendation votes are scheduled. No Vaccines for Children (VFC)
votes are scheduled. Agenda items are subject to change as priorities
dictate. For more information on the meeting agenda visit https://www.cdc.gov/vaccines/acip/meetings/meetings-info.html.
Public Participation
Interested persons or organizations are invited to participate by
submitting written views, recommendations, and data. Please note that
comments received, including attachments and other supporting
materials, are part of the public record and are subject to public
disclosure. Comments will be posted on https://www.regulations.gov.
Therefore, do not include any information in your comment or supporting
materials that you consider confidential or inappropriate for public
disclosure. If you include your name,
[[Page 71068]]
contact information, or other information that identifies you in the
body of your comments, that information will be on public display. CDC
will review all submissions and may choose to redact, or withhold,
submissions containing private or proprietary information such as
Social Security numbers, medical information, inappropriate language,
or duplicate/near duplicate examples of a mass-mail campaign. CDC will
carefully consider all comments submitted into the docket.
Written Public Comment: The docket will be opened to receive
written comments on December 14, 2021. Written comments must be
received on or before January 12, 2022.
Oral Public Comment: This meeting will include time for members of
the public to make an oral comment. Oral public comment will occur
before any scheduled votes including all votes relevant to the ACIP's
Affordable Care Act and Vaccines for Children Program roles. Priority
will be given to individuals who submit a request to make an oral
public comment before the meeting according to the procedures below.
Procedure for Oral Public Comment: All persons interested in making
an oral public comment at the January 12, 2022 ACIP meeting must submit
a request at https://www.cdc.gov/vaccines/acip/meetings/ no later than
11:59 p.m., EST, January 7, 2022, according to the instructions
provided.
If the number of persons requesting to speak is greater than can be
reasonably accommodated during the scheduled time, CDC will conduct a
lottery to determine the speakers for the scheduled public comment
session. CDC staff will notify individuals regarding their request to
speak by email by January 10, 2022. To accommodate the significant
interest in participation in the oral public comment session of ACIP
meetings, each speaker will be limited to 3 minutes, and each speaker
may only speak once per meeting.
The Director, Strategic Business Initiatives Unit, Office of the
Chief Operating Officer, Centers for Disease Control and Prevention,
has been delegated the authority to sign Federal Register notices
pertaining to announcements of meetings and other committee management
activities, for both the Centers for Disease Control and Prevention and
the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2021-26956 Filed 12-13-21; 8:45 am]
BILLING CODE 4163-18-P